FDA-approved neuromodulation system offers new hope for treatment-resistant depression at UAMS
Published on April 18, 2026.
The University of Arkansas for Medical Sciences (UAMS) is offering the SAINT neuromodulation system, an FDA-approved non-drug treatment for patients who have not responded to traditional treatments. The treatment uses targeted stimulation in parts of the brain implicated in depression, which can lead to broader effects over the course of treatment. UAMS was among the first in the country to offer the technology. The SAINT treatment can be personalized and involves 10 sessions a day for five days a week.
Related Articles
Woman Recalls Heartbreak of Learning She Had Ovarian Cancer Nearly 3 Decades Younger Than the Average Diagnosis
Vanja Wilson experienced heartbreaking emotions when she was diagnosed with ovarian cancer in her 30s, highlighting the lack of awareness and funding for the disease's survival rates.
Tick bites sending Americans to the ER at highest rate in nearly a decade, CDC says
Tick bites are increasing dramatically in the US, with increased emergency visits in Northeast, Midwest, and South America highlighting the dangers of multiple diseases.
New Alzheimer's treatments bring hope — and reminders of those we have lost
Aneuroomy, a complex, complex disease characterized by multiple causes, is a sad, yet hopeful story of loss and resilience, marked by new treatments and ongoing loss.